iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Research analysts at Wedbush increased their Q1 2025 earnings per share estimates for shares of iTeos Therapeutics in a research report issued on Wednesday, March 5th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.68) for the quarter, up from their prior estimate of ($0.79). Wedbush has a "Outperform" rating and a $25.00 price objective on the stock. The consensus estimate for iTeos Therapeutics' current full-year earnings is ($3.49) per share. Wedbush also issued estimates for iTeos Therapeutics' Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.77) EPS, Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($3.09) EPS, FY2026 earnings at ($3.95) EPS, FY2027 earnings at ($4.63) EPS and FY2028 earnings at ($4.32) EPS.
iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts' consensus estimates of ($1.14) by $0.13.
Other equities analysts have also issued research reports about the company. JPMorgan Chase & Co. lowered their price objective on iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating on the stock in a research note on Thursday, March 6th. Wells Fargo & Company lowered their price target on shares of iTeos Therapeutics from $19.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday, March 6th. Finally, HC Wainwright reissued a "buy" rating and issued a $46.00 price objective on shares of iTeos Therapeutics in a report on Thursday, March 6th.
View Our Latest Report on iTeos Therapeutics
iTeos Therapeutics Stock Up 6.5 %
Shares of iTeos Therapeutics stock traded up $0.46 on Monday, hitting $7.52. 671,594 shares of the company were exchanged, compared to its average volume of 453,291. The company has a 50-day moving average price of $7.50 and a 200 day moving average price of $9.20. The stock has a market capitalization of $287.22 million, a price-to-earnings ratio of -2.39 and a beta of 1.38. iTeos Therapeutics has a 1-year low of $6.67 and a 1-year high of $18.75.
Hedge Funds Weigh In On iTeos Therapeutics
Large investors have recently modified their holdings of the business. Algert Global LLC lifted its position in iTeos Therapeutics by 92.0% in the third quarter. Algert Global LLC now owns 256,139 shares of the company's stock valued at $2,615,000 after buying an additional 122,730 shares during the last quarter. State Street Corp lifted its holdings in shares of iTeos Therapeutics by 21.9% in the 3rd quarter. State Street Corp now owns 1,175,353 shares of the company's stock worth $12,000,000 after acquiring an additional 211,452 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of iTeos Therapeutics by 1.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 467,319 shares of the company's stock worth $4,771,000 after purchasing an additional 5,368 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in iTeos Therapeutics by 3.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 222,135 shares of the company's stock valued at $2,268,000 after purchasing an additional 8,397 shares during the last quarter. Finally, Readystate Asset Management LP raised its position in iTeos Therapeutics by 97.2% in the third quarter. Readystate Asset Management LP now owns 169,819 shares of the company's stock valued at $1,734,000 after purchasing an additional 83,700 shares during the period. Institutional investors and hedge funds own 97.16% of the company's stock.
About iTeos Therapeutics
(
Get Free Report)
iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Featured Articles
Before you consider iTeos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.
While iTeos Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
